Cellectar Biosciences, Inc. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (52)

View All

Latest Posts

About This Stock More About This Stock
Cellectar Biosciences Announces Pricing Of $8,000,000 Public Offering
Article By: NASDAQ GlobeNewswire
Wednesday, November 23, 2016 5:14 PM EDT
Cellectar Biosciences, Inc., today announces the pricing of an underwritten public offering of shares of its common stock.
In this article: CLRB Also: LTS
Read
Cellectar Biosciences Announces Pricing Of $7,000,000 Public Offering
Article By: NASDAQ GlobeNewswire
Friday, April 15, 2016 7:26 PM EDT
The company intends to use the net proceeds from the offering for general purposes, including continued development of its drug CLR 131 for multiple myeloma, and its proprietary phospholipid drug conjugate (PDC) delivery platform.
In this article: CLRB
Read
Cellectar Biosciences Announces 1-for-10 Reverse Stock Split
Article By: NASDAQ GlobeNewswire
Friday, March 4, 2016 1:49 PM EDT
Shares of Cellectar’s common stock will trade on a post-split basis beginning on March 7, 2016. The Company’s ticker symbol, CLRB, will remain unchanged. The new CUSIP number for Cellectar’s common stock post-reverse stock split will be 15117F302.
In this article: CLRB
Read
All Posts

Latest Tweets for $CLRB

No tweets yet!

PARTNER HEADLINES